Patents by Inventor Mark D. Parker

Mark D. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered glucosyltransferases
    Patent number: 11952598
    Abstract: Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: April 9, 2024
    Assignee: NUTRITION & BIOSCIENCES USA 4, INC.
    Inventors: Yougen Li, Mark S. Payne, Jared B. Parker, Slavko Kralj, Veli Alkan, Richard R. Bott, Robert Dicosimo, Qiong Cheng, Ellen D. Semke, Susan Marie Hennessey
  • Assay and method for quantitating carbonic anhydrase activity and assessing red blood hemolysis
    Patent number: 10246733
    Abstract: A method and assay for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and assay detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: April 2, 2019
    Assignee: CASE WESTERN UNIVERSITY
    Inventors: Ryan R. Geyer, Pan Zhao, Mark D. Parker, Walter F. Boron
  • ASSAY AND METHOD FOR QUANTITATING CARBONIC ANHYDRASE ACTIVITY AND ASSESSING RED BLOOD HEMOLYSIS
    Publication number: 20160355867
    Abstract: A method and assay for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and assay detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis.
    Type: Application
    Filed: June 6, 2016
    Publication date: December 8, 2016
    Inventors: Ryan R. Geyer, Pan Zhao, Mark D. Parker, Walter F. Boron